Search Immortality Topics:

Page 8,116«..1020..8,1158,1168,1178,118..8,1308,140..»

International Stem Cell Corporation (ISCO) Announces That Donna Queen, Former President and CEO of ZO SKIN HEALTH, the Luxury Brand Created by Zein Obagi, MD, Has Joined ISCO Executive Team

Posted: June 19, 2011 at 4:00 pm

International Stem Cell Corporation (OTCBB:ISCOE) announced today that Donna Queen has joined ISCO’s executive team. Ms. Queen will be primarily responsible for ISCO’s wholly owned subsidiary Lifeline Skin Care’s (Lifeline) brand identity and international marketing as well as broadening the range of Lifeline products currently available.


Prior to joining ISCO, Ms. Queen was President and CEO of ZO SKIN HEALTH® by Zein Obagi, MD. Dr. Obagi is the dermatologist who created the original Obagi Nu-Derm skincare system, which has since become the leading physician-dispensed brand of anti-aging skincare. Earlier Ms. Queen founded and led one of Virginia’s largest advertising and marketing agencies, specializing in aesthetic and dermatological marketing and brand development.


Dr. Andrey Semechkin, President and CEO of ISCO, commented: “I’m very pleased that Ms. Queen has joined our team. Ms. Queen’s industry experience and expertise particularly in marketing prescription-based products will be invaluable as we expand our skin care business and further enhance our line of products.”


Ms. Queen adds, “I’m very excited to be joining such a dynamic, science-driven company. There have been no recent meaningful technological breakthroughs in skin care, but with ISCO’s scientific leadership in stem cells and their knowledge of skin tissue physiology we have an opportunity to continue to deliver new and innovative treatments.”


ISCO previously announced sales of approximately $1.1 million from the pilot direct-to-consumer launch of Lifeline’s first two products, an anti-aging Day Serum and a Night Serum. These products were developed by ISCO’s scientific research team in collaboration with internationally recognized cosmetics experts. The serums contain an extract from ISCO?s proprietary human parthenogenetic stem cells combined with antioxidants and botanically derived ingredients. Using these serums on a regular basis provides significant benefits to the skin including improvement in skin tone and elasticity and the improvement in the appearance of fine lines and wrinkles, results that have been independently established by clinical studies performed at industry-leading testing laboratories. The serums can be purchased by visiting Lifeline?s website at http://www.lifelineskincare.com and are also available at selected luxury spas and physicians’ offices in the United States.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


Forward-looking Statements
Statements pertaining to anticipated developments, product development and marketing plans, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, competition, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.


http://cts.businesswire.com/ct/CT?id=bwnews&sty=20110616005464r1&sid=14230&distro=ftp
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, PhD
Vice President, ISCO
CEO, Lifeline Skin Care
[email protected]

or
Simon Craw, PhD
Vice President, ISCO
[email protected]
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
[email protected]

Recommendation and review posted by Fredricko

International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16

Posted: June 19, 2011 at 4:00 pm


International Stem Cell Corporation (OTCBB:ISCOE) announced today that Kenneth Aldrich, Chairman, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011 at 10:30 a.m. Eastern.

A webcast of the presentation will be accessible online at http://www.internationalstemcell.com, or the PrecisionIR event site: http://www.vcall.com/CustomEvent/lipper/index.aspAn archived version will be available for 30 days.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
[email protected]

or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
[email protected]

Recommendation and review posted by Fredricko

International Stem Cell Corporation Discovers Method to Produce Uncontaminated Liver Cells: New Platform to Produce Various Cell Types Free From Undifferentiated, Potentially Tumorigenic, Cells

Posted: June 19, 2011 at 4:00 pm

Recommendation and review posted by Fredricko

International Stem Cell to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on June 16

Posted: June 19, 2011 at 4:00 pm


International Stem Cell Corporation (OTCBB:ISCOE) announced today that Kenneth Aldrich, Chairman, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011 at 10:30 a.m. Eastern.

A webcast of the presentation will be accessible online at http://www.internationalstemcell.com, or the PrecisionIR event site: http://www.vcall.com/CustomEvent/lipper/index.aspAn archived version will be available for 30 days.

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
[email protected]

or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
[email protected]

Recommendation and review posted by Fredricko

Drug companies trying to "create" parasites for treating ulcerative colitis

Posted: June 19, 2011 at 3:58 pm

Ulcerative colitis, a type of inflammatory bowel disease (IBD), is less common in countries endemic for helminth infections, suggesting that helminth colonization may have the potential to regulate intestinal inflammation in IBD. Therapeutic effects of experimental helminth infection have been reported.

According to a researcher: “What we found was that after worm infection, the regions of the colon that were previously not making mucus, were now making mucus again.”

“That’s a key factor in healing, and it looked like the mucus came back because the worms were causing the body to produce IL-22. This is a molecule that promotes epithelial growth and healing.”
Studies suggest parasites can regulate the immune system in ways that prevent it from “going wild” and attacking healthy tissue, and possibly human evolution took that into account.

A case report in the journal Science Translational Medicine provides a cellular and molecular portrait of dynamic changes in the intestinal mucosa of an individual who infected himself with Trichuris trichiura to treat his symptoms of ulcerative colitis.

Tissue with active colitis had a prominent population of mucosal T helper (TH) cells that produced the inflammatory cytokine interleukin-17 (IL-17) but not IL-22, a cytokine involved in mucosal healing.

After helminth exposure, the disease went into remission, and IL-22–producing TH cells accumulated in the mucosa. Genes involved in carbohydrate and lipid metabolism were up-regulated in helminth-colonized tissue, whereas tissues with active colitis showed up-regulation of proinflammatory genes such as IL-17, IL-13RA2, and CHI3L1.

T. trichiura colonization of the intestine may reduce symptomatic colitis by promoting goblet cell hyperplasia and mucus production through TH2 cytokines and IL-22. Controlled helminth infections may lead to new therapies for inflammatory bowel diseases.

References:

Eat Your Worms: The Upside Of Parasites. NPR.

M. J. Broadhurst, J. M. Leung, V. Kashyap, J. M. McCune, U. Mahadevan, J. H. McKerrow, P. Loke, IL-22+ CD4+ T Cells Are Associated with Therapeutic Trichuris trichiura Infection in an Ulcerative Colitis Patient. Sci. Transl. Med. 2, 60ra88 (2010).

Image source: Trichuris egg in stool sample (40x). Wikipedia, GNU Free Documentation License, Version 1.2.

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Recommendation and review posted by G. Smith

Memorable medical textbooks of the past

Posted: June 19, 2011 at 3:58 pm

Medical textbooks were not always as dreary and as bland as they are now, according to BMJ. Some examples of lively, first person didactic tone come from J L Burton’s Essentials of Dermatology:

“The Lord Privy Seal is neither a lord, nor a privy, nor a seal” and “‘seborrhoeic’ warts have no relationship to seborrhoea.”

“The simultaneous occurrence of scabies in a doctor and a nurse may mean that they have shared nothing more exciting than a patient with Norwegian scabies.”

Explanation:
The Lord Privy Seal (or, more formally, the Lord Keeper of the Privy Seal) is the fifth of the Great Officers of State in the United Kingdom. Originally, its holder was responsible for the monarch’s personal (privy) seal (as opposed to the Great Seal of the Realm). Though one of the oldest offices in government anywhere, it has no particular function today.
Seborrhoeic keratosis (seborrhoeic wart, basal cell papilloma) is a benign overgrowth of the basal cells of the epidermis. The patient is usually elderly and concerned because the lesion is unsightly.

References:

Image source: Seborrheic keratosis, Wikipedia, GNU Free Documentation License, Version 1.2.

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Recommendation and review posted by G. Smith


Page 8,116«..1020..8,1158,1168,1178,118..8,1308,140..»